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Abstract
Background Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient 
and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, 
few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different 
management approaches within universal healthcare systems.
Objective Our objective was to use real-world data to describe the costs associated with the treatment of schizophrenia in 
adults receiving atypical antipsychotics in Brazil from 2000 to 2010.
Methods We integrated three national databases for adult patients with schizophrenia receiving one or more atypical antipsy-
chotics. We assessed only direct medical costs and the study was conducted from a public-payer perspective. A multivariate 
log-linear regression model was performed to evaluate associations between costs and clinical and demographic variables.
Results We identified 174,310 patients with schizophrenia, with mean ± standard deviation (SD) annual costs of $US1811.92 
± 284.39 per patient. Atypical antipsychotics accounted for 79.7% of total costs, with a mean annual cost per patient 
of $US1578.74 ± 240.40. Mean annual costs per patient were $US2482.90 ± 302.92 for psychiatric hospitalization and 
$US862.96 ± 160.18 for outpatient psychiatric care. Olanzapine was used by 47.7% of patients and represented 62.8% of the 
total costs of atypical antipsychotics. Patients who used clozapine had the highest mean annual cost per patient for outpatient 
psychiatric care and psychiatric hospitalization.
Conclusions Atypical antipsychotics were responsible for the majority of the schizophrenia treatment costs, and psychiatric 
hospitalization costs were the highest mean annual cost per patient. Authorities should ensure efficient use of atypical antip-
sychotics and encourage outpatient psychiatric care over psychiatric hospitalization where possible.
Key Points for Decision Makers 
Atypical antipsychotics were the largest contribu-
tor (approximately 80%) to direct medical costs for 
patients with schizophrenia in this Brazilian cohort, with 
psychiatric hospitalization accounting for the largest 
cost category per patient. However, costs of atypical 
antipsychotics will fall as generics become increasingly 
available.
It is essential that health services seek to optimize the 
use of atypical antipsychotic medicines and outpatient 
services to maximise patient care within finite resources.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 8-018-0408-4) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Schizophrenia is a severe and debilitating mental disorder 
that affects approximately 0.3–0.7% of the population [1] 
and is one of the leading causes of years lived with dis-
ability worldwide [2]. People with schizophrenia present 
changes in thinking, feeling, and behaviour. Its manifes-
tations are usually divided into positive symptoms (e.g. 
hallucinations and delusions), negative symptoms (e.g. 
diminished emotional expression and lack of motivation) 
[1, 3, 4] and cognitive symptoms (e.g. problems with 
working memory and executive functioning) [3], but no 
single symptom is pathognomonic of the disorder [1].
Schizophrenia is associated with a significant economic 
burden. In the USA, estimated costs of $US62.7 billion 
were related to the disease in 2002, reaching $US155.7 
billion in 2013. This included direct costs related to the 
care of the disorder, including hospital inpatient stays, 
emergency room visits, outpatient visits and prescription 
medicines. Direct non-healthcare costs and mental disor-
der-related indirect costs are also substantial [5, 6]. The 
mean monthly costs per patient on treatment with schizo-
phrenia is typically more than four times higher than those 
for the population as a whole with similar demographics 
but without schizophrenia [7].
The treatment of schizophrenia generally includes 
antipsychotic medicines, increasingly atypical antipsy-
chotics, coupled with psychological and psychosocial 
interventions [3, 8]. The Brazilian National Health Sys-
tem [NHS (Sistema Único de Saúde; SUS)] provides—in 
addition to hospital and outpatient care—typical antipsy-
chotics, or first-generation antipsychotics, such as chlor-
promazine and haloperidol, and atypical antipsychotics, or 
second-generation antipsychotics (SGA), in oral formula-
tions. This includes oral clozapine, olanzapine, quetiapine, 
risperidone and ziprasidone but not—for instance—ari-
piprazole, long-acting atypical antipsychotics or inject-
able atypical antipsychotics. These SGAs are considered 
high-cost or specialized medicines and are dispensed to 
patients after an analysis of compliance as required by the 
national clinical guidelines for the treatment of schizo-
phrenia [9–12]. This strategy aims to rationalize treat-
ment resource utilization for both medical and financial 
reasons [13]. For patients meeting the requirements, SGAs 
are fully funded by the SUS (public payer), otherwise the 
prescribed medicines are fully funded by the patients 
themselves.
Several studies have shown that medicine costs account 
for approximately 25% of direct costs related to the treat-
ment of schizophrenia [5–7, 14], highlighting the impor-
tance of antipsychotic medicines when evaluating different 
management approaches for patients with schizophrenia 
[7, 14]. In Brazil, a study performed from the SUS national 
database between 2000 and 2004 reported olanzapine and 
risperidone were among the highest cost medicines most 
dispensed, accounting for 8.6% of annual expenditure on 
high-cost drugs [15]. From August 2012 to July 2013, the 
SUS spent an estimated $US181 million [converted using 
the purchasing power parity (PPP) conversion factor of the 
World Bank of 2012, $US1 = 1.559 Brazilian Real (BRL)] 
[16] on atypical antipsychotics alone, representing 7.3% of 
the total amount spent on high-cost drugs in Brazil during 
that period [12]. Other Brazilian studies have evaluated 
the costs associated with the use of antipsychotics, albeit 
with considerable methodological heterogeneity and with 
different objectives [17–19].
Considering the impact of schizophrenia on the patient 
and society, and the need to understand the allocation of 
health resources for the treatment of this mental disorder 
within a universal healthcare system with finite resources, 
our objective was to describe the costs associated with the 
treatment of schizophrenia in adults receiving atypical antip-
sychotics through real-world data. In this way, we aimed to 
gain an accurate picture of actual costs rather than relying 
on modelling approaches to compile the resource picture.
2  Methods
2.1  Study Design and Population
This study is an evaluation of the costs associated with the 
use of high-cost drugs and outpatient and hospital services 
in Brazil through a national non-concurrent open cohort of 
adult patients with schizophrenia receiving atypical antip-
sychotics, from January 2000 to December 2010. The time 
period of the cohort was determined by the data available 
within the SUS national administrative databases. Atypi-
cal antipsychotics were chosen because of the requirements 
for their funding within the SUS and their current contribu-
tion to expenditure on high-cost drugs in Brazil. Clozapine, 
olanzapine and risperidone have been available in the SUS 
since the second half of the 1990s [20–23], and quetiapine 
and ziprasidone were incorporated into the SUS in 2002 [9, 
10]. The first generic risperidone was available in Brazil 
in 2004, with generic clozapine, olanzapine and quetiapine 
available in the second half of 2010 and generic ziprasidone 
in 2013 [24].
This cohort was built via integration through determin-
istic-probabilistic linkage records from the Mortality Infor-
mation System (SIM) and two SUS national administrative 
databases: (1) the Ambulatory Information System (SIA/
SUS), which includes data on outpatient procedures and 
provision of high-cost drugs, and (2) the Hospital Informa-
tion System (SIH/SUS). The linkage aims to find records 
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for the same patient in different files and unify them as a 
single record in a database. Deterministic linkage is used 
when records are reliable and able to be compared, whereas 
probabilistic linkage is used when records have problems 
of consistency, errors or undeclared information [25]. This 
methodology has been described in other studies [25–28].
Patients were included if they (1) received one or more 
of the following atypical antipsychotics: clozapine [ana-
tomical therapeutic chemical (ATC) code: N05AH02], 
olanzapine (N05AH03), quetiapine (N05AH04), risperidone 
(N05AX08) or ziprasidone (N05AE04); (2) were diagnosed 
with one of the following diseases according to the Inter-
national Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision (ICD-10): paranoid schizo-
phrenia (F20.0), hebephrenic schizophrenia (F20.1), cata-
tonic schizophrenia (F20.2), undifferentiated schizophrenia 
(F20.3), post-schizophrenic depression (F20.4), residual 
schizophrenia (F20.5), simple schizophrenia (F20.6) or other 
schizophrenia (F20.8); and (3) were treated between Janu-
ary 2000 and December 2010. These atypical antipsychotics 
were chosen as they are currently available via the SUS. The 
exclusion criteria were (1) patients taking atypical antip-
sychotics drugs for other ICD-10 codes, (2) patients aged 
< 18 years and (3) patients who have not received atypical 
antipsychotics for at least 12 months, continuously or not, 
during the 11-year follow-up. All patients who met the inclu-
sion criteria and not the exclusion criteria were included in 
the cohort.
Entry date was defined as the date of the first registration 
of dispensing of an atypical antipsychotic drug in the SIA, 
and the date of the loss to follow-up was defined as the date 
of the last patient record in the SIA or SIH, death (SIM) or 
31 December 2010 (censoring right).
2.2  Cost Analysis
The SIA processes all production of outpatient care or dis-
pensing of high-cost drugs, and the SIH processes all pro-
duction related to patient care in hospitals. The term produc-
tion refers to procedures that are performed during patient 
care, which may include materials and drugs used, health 
professionals involved and hotel structure in case of hospi-
talization. Consequently, each procedure or high-cost drug 
used and registered for each individual in the SUS national 
databases (SIA and SIH) brings with it some information 
such as description of the procedure and its value or high-
cost drug for use in 30 days and its value [29, 30].
In Brazil, high-cost drugs refer to those for chronic 
diseases, whose unit costs or costs of all treatment are 
considered high [13], which includes the atypical antip-
sychotics. In our study, outpatient procedures comprise 
both outpatient psychiatric care (e.g. Psychosocial Care 
Center) and other outpatient care such as outpatient 
non-psychiatric care to which patients may have access. 
Finally, hospital procedures include psychiatric hospi-
talizations in a general or psychiatric hospital and other 
hospitalizations, which were defined as non-psychiatric 
hospitalization.
All financial resources from the outpatient or hospital 
procedures and the high-cost drugs used by the patient 
were summed to calculate the total cost for the study 
period. In other words, a micro-cost approach (bottom-up 
costing) [31] was used to estimate the direct healthcare 
costs with respect to high-cost drugs and outpatient and 
hospital procedures from the SUS databases (SIA and 
SIH) used by each patient with schizophrenia.
Monetary values were adjusted using the PPP conver-
sion factor of the World Bank. PPP rates have an annual 
periodicity and provide a standard measure with which 
expenditure levels can be compared between countries. 
We adjusted the cost values of each year using the PPP 
rate for that respective year, i.e. for cost values of the year 
2000, we used the year 2000 PPP rate: $US1 = 0.759 BRL; 
in 2001: $US1 = 0.803 BRL, and so on [16]. The cost 
analysis was from a public-payer perspective, according 
to Brazilian Ministry of Health recommendations [31].
The Brazilian NHS is financed by the federal govern-
ment, states and municipalities. In addition, citizens also 
participate directly in health financing when using the pri-
vate health system, through health insurance, co-payment 
or directly paying for the medicine or health procedure. 
The federal government is the main funder of the public 
health system in Brazil, and the high-cost drugs and proce-
dures registered in the SUS databases (SIA and SIH) used 
in this study are funded by the federal government [32].
Individual costs were characterized by sex, age group, 
geographic region of residence, primary diagnosis (ICD-
10), first atypical antipsychotic used and period of study 
entry. Moreover, we also characterized costs by type of 
end of follow-up (censoring or death), psychotic outbreak, 
drug switching (change of atypical antipsychotic during 
follow-up) and cause of death. Censoring and death report 
how the patient’s follow-up ended, i.e. censoring right, 
censoring due to the last record and no patient return to 
cohort or death. Psychotic outbreaks were defined accord-
ing to the patient’s psychiatric hospitalization record.
Subsequently, we stratified the individual costs by 
procedure category (atypical antipsychotics, other high-
cost drugs dispensed, outpatient psychiatric care, other 
outpatient care, psychiatric hospitalizations and other 
hospitalizations) and distributed these categories by their 
follow-up year. Finally, considering the intention-to-treat 
(ITT) perspective, we grouped costs according to proce-
dure category by the atypical antipsychotic at study entry.
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2.3  Statistical Analysis
Demographic (sex, age, geographic region and period at 
study entry) and clinical [primary diagnosis (ICD-10) at 
study entry, atypical antipsychotic at study entry, events, end 
of follow-up and cause of death] variables were described as 
frequencies, measures of central tendency (mean) and varia-
bility ± standard deviation (SD). The relative proportions of 
the total costs were calculated for each procedure category. 
The individual costs were described based on measures of 
central tendency, (mean and median) annual cost per patient, 
and variability ± SD and interquartile range (IQR).
A multivariate log-linear regression model was performed 
to evaluate associations between the mean annual cost per 
patient and clinical and demographic variables. Variables 
with p ≤ 0.20 in the univariate analysis were selected to 
start multivariate modelling with sequential deleting of each 
variable until only those with p < 0.05 remained in the final 
model. For the identification of comorbidities, we used the 
indicators developed by Elixhauser et al. [33] and updated 
by Quan et al. [34]. The adequacy of the final model was 
verified by residuals profile analysis, and our results are 
presented in the Table S1 in the electronic supplementary 
material (ESM) and as percentage differences (PDs) [PD = 
 (eLn(Regression Coeff.) − 1) × 100] and 95% confidence intervals.
Statistical analysis was performed using Microsoft Excel 
(Microsoft Corporation, Redmond, WA, USA), MySQL 5.5 
database management system (Oracle Corporation, Red-
wood, CA, USA) and R Program 3.4.2 (R Core Team 2017, 
Vienna, Austria).
2.4  Ethical Approval
This study was approved by the Ethics Committee of 
the Federal University of Minas Gerais, Brazil (no. 
1072253/2015).
3  Results
3.1  Patient Characteristics
During the 11-year follow-up period, we identified 174,310 
patients with schizophrenia who used atypical antipsychot-
ics provided by the SUS, with a mean ± SD annual cost of 
$US1811.92 ± 284.39 per patient. The mean age at study 
entry was 42.7 ± 17.5 years (male 38.9 ± 16.1; female 46.8 
± 18.1), and the median was 40 years; 63.0% of the popula-
tion was aged 18–45 years; 51.7% were male; and 64.4% 
lived in the Southeast region of Brazil. The mean annual 
cost per patient was highest between 18 and 45 years of 
age at study entry. In addition, the mean annual cost per 
patient was higher for men ($US1914.84 ± 304.74) and for 
individuals residing in the Southeast region ($US1867.57 ± 
287.10). In this cohort, 44.7% of patients entered the study 
from 2004 to 2007, but the highest mean annual cost per 
patient ($US1957.62 ± 359.46) was for patients who entered 
the study from 2000 to 2003 (Table 1).
In the present study, 66.5% of individuals were diagnosed 
with paranoid schizophrenia (F20.0). However, patients 
diagnosed with residual schizophrenia (F20.5) had the high-
est mean annual cost per patient ($US1925.06 ± 347.96). 
The most dispensed atypical antipsychotic at study entry was 
olanzapine (37.1%), followed by risperidone (36.3%), que-
tiapine (12.9%), ziprasidone (8.0%) and clozapine (5.0%), 
and 0.7% of patients used more than one atypical antipsy-
chotic at study entry. In the ITT analysis, patients receiving 
more than one atypical antipsychotic had the highest mean 
annual cost per patient ($US2355.97 ± 800.60), followed 
by those receiving olanzapine ($US2252.59 ± 547.80), clo-
zapine ($US1909.91 ± 334.60), ziprasidone ($US1842.44 ± 
809.14), quetiapine ($US1748.97 ± 795.15) and risperidone 
($US1195.99 ± 276.58) (Table 1).
The proportion of patients censoring at the end of 
follow-up was 86.2%, presenting a mean annual cost per 
patient of $US1796.80 ± 288.20. However, the mean ± SD 
annual cost per patient was higher for individuals who died 
($US1978.58 ± 243.14). According to the ICD-10 groups, 
the main causes of death were other degenerative diseases 
of the nervous system (10.7%), influenza and pneumonia 
(8.7%) and ischemic heart disease (8.5%). Patients who had 
diabetes mellitus recorded as cause of death (4.4%) had a 
mean annual cost of $US2186.81 ± 581.45 (Table 1).
3.2  High‑Cost Drug Dispensing and Health Services 
Utilization
In this cohort, 32.3% of patients used outpatient care and 
20.9% were hospitalized. High-cost drugs accounted for 
84.9% of total costs in patients with schizophrenia, followed 
by hospitalizations (7.8%) and outpatient care (7.2%).
Considering the procedure categories, atypical antipsy-
chotics accounted for 79.7% of the total costs of treating 
patients, followed by outpatient psychiatric care (6.0%) and 
psychiatric hospitalization (5.6%). The mean annual cost 
per patient for atypical antipsychotics was $US1578.74 ± 
240.40, and the median was $US1235.86. Mean annual per-
patient costs for outpatient psychiatric care and psychiatric 
hospitalization, respectively, were $US862.96 ± 160.18 
(median $US396.52) and $US2482.90 ± 302.92 (median 
$US1313.94) (Table 2).
Psychiatric treatment accounted for 71.4% of the total cost 
for inpatients and for 83.1% of the total cost for outpatients.
Patients who used olanzapine had the highest mean ± SD 
annual costs per patient ($US2085.28 ± 485.62; median 
$US2006.81) for atypical antipsychotics. Patients who used 
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Table 1  Mean annual cost per 
patient according to clinical 
and demographic variables of 
patients with schizophrenia who 
used atypical antipsychotics 
provided by the Brazilian 
National Health System 
(SUS). Brazil, 2000–2010 (n = 
174,310)
Values were converted to $US and adjusted using the purchasing power parity rate (World Bank)
ICD-10 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; 
NS nervous system, SD standard deviation
Variables N (%) Mean annual cost ± SD 
per patient, $US
The whole cohort 174,310 (100.0) 1811.92 ± 284.39
Sex
 Male 90,131 (51.7) 1914.84 ± 304.74
 Female 84,179 (48.3) 1672.47 ± 266.66
Age group at study entry, years
 18–25 29,692 (17.0) 1852.34 ± 295.58
 26–35 40,967 (23.5) 1892.33 ± 287.49
 36–45 39,173 (22.5) 1857.03 ± 316.15
 46–55 27,626 (15.9) 1735.18 ± 317.17
 56–65 13,998 (8.0) 1669.80 ± 269.51
 > 65 22,854 (13.1) 1397.98 ± 294.05
Geographic region at study entry
 Southeast 112,254 (64.4) 1867.57 ± 287.10
 Northeast 27,507 (15.8) 1727.58 ± 318.31
 South 19,091 (10.9) 1600.46 ± 292.30
 Midwest 12,313 (7.1) 1790.39 ± 283.15
 North 3145 (1.8) 1488.75 ± 328.43
Period of study entry, years
 2000–2003 33,766 (19.4) 1957.62 ± 359.46
 2004–2007 77,894 (44.7) 1728.74 ± 413.57
 2008–2010 62,650 (35.9) 1529.68 ± 526.88
Primary diagnosis (ICD-10) at study entry
 Paranoid schizophrenia (F20.0) 115,862 (66.5) 1836.89 ± 315.13
 Simple schizophrenia (F20.6) 30,771 (17.6) 1699.74 ± 411.54
 Other schizophrenia (F20.8) 11,926 (6.8) 1836.30 ± 384.72
 Residual schizophrenia (F20.5) 6625 (3.8) 1925.06 ± 347.96
 Hebephrenic schizophrenia (F20.1) 5152 (3.0) 1917.98 ± 343.57
 Undifferentiated schizophrenia (F20.3) 2123 (1.2) 1647.27 ± 377.01
 Catatonic schizophrenia (F20.2) 1000 (0.6) 1806.59 ± 299.28
 Post-schizophrenic depression (F20.4) 851 (0.5) 1774.54 ± 347.26
Atypical antipsychotic at study entry
 Olanzapine 64,652 (37.1) 2252.59 ± 547.80
 Risperidone 63,361 (36.3) 1195.99 ± 276.58
 Quetiapine 22,501 (12.9) 1748.97 ± 795.15
 Ziprasidone 13,884 (8.0) 1842.44 ± 809.14
 Clozapine 8692 (5.0) 1909.91 ± 334.60
 More than one atypical antipsychotic 1220 (0.7) 2355.97 ± 800.60
Events
 Drug switching 48,648 (27.9) 2161.56 ± 276.57
 Psychotic outbreak 25,213 (14.5) 2313.06 ± 399.41
End of follow-up
 Censoring 150,270 (86.2) 1796.80 ± 288.20
 Death 24,040 (13.8) 1978.58 ± 243.14
Cause of death (ICD-10 groups)
 Other degenerative diseases of the NS 2585 (10.7) 1604.01 ± 330.28
 Influenza and pneumonia 2089 (8.7) 1823.03 ± 461.70
 Ischemic heart disease 2055 (8.5) 1574.67 ± 306.82
 Cerebrovascular diseases 1897 (7.9) 1986.59 ± 343.62
 Unclear cause 1245 (5.2) 1810.94 ± 323.80)
 Diabetes mellitus 1049 (4.4) 2186.81 ± 581.45
 Other groups 13,120 (54.6) 2069.47 ± 262.92
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clozapine had the highest mean annual cost per patient 
($US1105.39 ± 236.70; median $US550.60) for outpatient 
psychiatric care and the highest mean annual cost per patient 
($US3509.34 ± 854.21; median $US1842.45) for psychiatric 
hospitalization (Table 3).
Patients who used risperidone consumed the highest per-
centage (20.1%) of outpatient psychiatric care, and 14.1% of 
those who used clozapine underwent at least one psychiatric 
hospitalization. Patients who used quetiapine had the lowest 
percentage of outpatient psychiatric care (9.7%) and psychi-
atric hospitalizations (6.4%). However, patients who used 
quetiapine used the highest percentage of other high-cost 
drugs (31.0%) (Table 3).
Most patients (72.1%) remained on their atypical antipsy-
chotic at study entry. The highest percentage of permanence 
on atypical antipsychotic treatment was observed for patients 
receiving olanzapine (27.9%), followed by those receiving 
risperidone (25.4%), quetiapine (10.3%), ziprasidone (5.0%) 
and clozapine (3.6%).
During the 11-year follow-up, the mean annual cost 
per patient for hospital procedures appeared to generally 
increase, with an emphasis on psychiatric hospitalizations. 
On the other hand, the mean annual cost per patient with 
high-cost drugs, such as atypical antipsychotics, and out-
patient care, such as outpatient psychiatric care, tended to 
fall (Fig. 1).
3.3  Multivariate Analysis
Male patients were associated with an increase of approxi-
mately 11% in the mean annual costs per patient (PD 11.51, 
p < 0.001), whereas patients aged 46–65 years were associ-
ated with a decrease in mean annual costs per patient. The 
variables drug switching (103.07, p < 0.001), psychotic out-
break (52.89, p < 0.001), comorbidities (19.37, p < 0.001) 
and death (32.22, p <0.001) were also associated with an 
increase in the mean annual costs per patient (Fig. 2).
For each year in the cohort, an increase of approximately 
7% in the mean annual costs per patient (6.61, p < 0.001) 
was observed, and registration of psychiatric care before 
starting the antipsychotic treatment was associated with an 
increase of approximately 25% in the mean annual costs per 
patient (25.14, p < 0.001) (Fig. 2).
Patients who used risperidone at study entry were asso-
ciated with a reduction of approximately 81% in the mean 
annual costs per patient (− 80.94, p < 0.001) compared with 
patients who used more than one atypical antipsychotic at 
study entry. Conversely, the use of clozapine (10.31, p < 
0.01), olanzapine (83.13, p < 0.001), quetiapine (64.04, p < 
0.001) and ziprasidone (70.64, p < 0.001) at study entry was 
associated with an increase in mean annual costs per patient.
Furthermore, patients who used other high-cost drugs 
during follow-up presented an increase of 60% in the mean 
annual costs per patient (60.00, p < 0.001) (Fig. 2).
Approximately 51% (R2 = 0.5099) of the variability of 
the mean annual cost per patient was explained by the best 
fitted model (p < 0.001) (Table S1 in the ESM, and Fig. 2).
4  Discussion
In this study, we identified and described the treatment costs 
of more than 174,000 patients who used atypical antipsy-
chotic drugs for schizophrenia through the Brazilian NHS 
(SUS). The literature surrounding the treatment of schizo-
phrenia in the real world is scarce, and this study was under-
taken to address this issue in Brazil using large administra-
tive databases (big data) as an information source. Although 
the term big data has gained prominence in recent years, its 
use in health economics and outcomes research requires fur-
ther encouragement [35]. With regard to the optimization of 
financial resources, we believe the results of this study will 
encourage national health services in Brazil and globally 
to focus on policies aimed at improving the rational use of 
Table 2  Cost per patient 
receiving schizophrenia 
treatment, according to the 
category of procedure during 
the follow-up period. Brazil, 
2000–2010 (n = 174,310)
Values were converted to $US and adjusted using the purchasing power parity rate (World Bank)
IQR interquartile range, SD standard deviation
a Mean annual cost per patient
b Median annual cost per patient
c Proportion of total costs
Category of procedure Patients, N (%) Cost ($US)
Meana (SD) Medianb (IQR 1; IQR 3) %c
Atypical antipsychotics 174,310 (100.0) 1578.74 (240.40) 1235.86 (1001.12; 1341.90) 79.7
Outpatient psychiatric care 30,292 (17.4) 862.96 (160.18) 396.52 (342.01; 420.31) 6.0
Psychiatric hospitalization 19,212 (11.0) 2482.90 (302.92) 1313.94 (1283.82; 1344.95) 5.6
Other high-cost drugs 26,820 (15.4) 924.04 (151.07) 272.58 (189.00; 537.54) 5.2
Other hospitalizations 20,834 (12.0) 1266.99 (201.58) 450.07 (420.17; 453.16) 2.2
Other outpatient care 31,330 (18.0) 345.75 (35.80) 50.32 (39.75; 63.52) 1.2
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atypical antipsychotic medicines with increasing availabil-
ity of generic oral antipsychotic medicines and the use of 
outpatient psychiatric care over psychiatric hospitalizations 
where possible.
During the 11-year follow-up of patients with schizo-
phrenia receiving atypical antipsychotics, these drugs repre-
sented the largest proportion of direct healthcare costs in the 
treatment of schizophrenia. Overall, the cost of medicines 
was responsible for approximately 85% of the total direct 
medical costs (Table 2) and was the main determinant of 
the mean annual cost per patient (Table S1 in the ESM, and 
Fig. 2). Knapp et al. [36] conducted a systematic review and 
showed that, in general, spending on medicines in coun-
tries with higher incomes ranged from 1.1 to 9.0% of all 
direct healthcare costs in patients with schizophrenia and 
that this difference was related to the extent and methods by 
which expenditures were determined, the pricing policies, 
the available medicines and the health service structure of 
each country. According to their systematic review, the cost 
of medicines tends to be higher in countries where services 
are more limited and where the cost of inpatient treatment 
is lower. However, the reviewed papers were published 
between 1992 and 1997, before atypical antipsychotics and 
care in the community became established [36].
Our findings contrast with those from more recent studies 
that indicated medicine costs accounted for approximately 
25% of direct healthcare costs of patients with schizophrenia 
[6, 7, 14]. In Brazil, Razzouk et al. [18] stated that spending 
on antipsychotic drugs in patients with psychotic disorders 
may account for about 50% of direct health costs in the SUS. 
Even considering the methodological particularities of the 
cost studies, mainly with regard to the cost components 
of each, one reason for the higher burden of medicines in 
our study could be that some patients are receiving their 
pharmacotherapy via the SUS and using the private sector 
(health plan or direct payment) for outpatient and hospital 
treatment, since health plans in Brazil usually do not provide 
for continuous use medication such as antipsychotic drugs. 
In 2000, a total of 18.2% of the Brazilian population had a 
private health plan, and this increased to 23.6% in 2010 [37, 
38]. Another fact that may well have influenced these costs 
is that, between 2000 and 2010, the period of this cohort, 
many atypical antipsychotics were under patent protec-
tion (originator antipsychotics); this is changing, and their 
related mean annual expenditure per patient is now falling 
(Fig. 1) as seen with risperidone. Studies analysing antipsy-
chotic prescriptions over time have also shown a decrease in 
expenditure. For example, the costs of risperidone appreci-
ably fell in Western Europe after generics became available. 
This was also often accompanied by a fall in the price of 
originator risperidone [39–43].
Several studies have compared atypical antipsychotics 
and found medication-specific adverse reactions, which 
could affect costs, and limited differences with respect to 
their efficacy [44–49]. Based on these differences, some 
studies have questioned the utility of broadly characterizing 
new-generation antipsychotic drugs as atypicals, as these 
drugs are not homogeneous [50, 51]. Thus, it is clear that 
Fig. 1  Mean annual cost per 
patient according to the pro-
cedure category and the year 
of follow-up, adjusted by the 
purchasing power parity rate. 
Brazil, 2000–2010
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additional studies are needed to better understand the dif-
ference in the percentage of total cost and the mean annual 
cost per patient for atypical antipsychotic drugs, especially 
between olanzapine and risperidone, building on our find-
ings. New studies will further assist decision makers in 
allocating healthcare resources and understanding whether 
differences in the mean annual costs per patient for the dif-
ferent atypical antipsychotics are accompanied by benefits 
for patients, their families and the general population. Hav-
ing said this, we are aware that the atypical antipsychotic 
treatments chosen should be based on the characteristics of 
both the patient and the medicine rather than advocating a 
particular atypical antipsychotic as first-line treatment [52, 
53]. This is apart from clozapine, which is typically reserved 
for refractory cases.
In Brazil, unlike previous clinical protocols guiding 
schizophrenia treatment during the period of this cohort 
[9, 10], the current clinical guideline does not recommend 
a specific treatment pathway [11], similar to other guide-
lines [3, 8]. The only exception in Brazil is regarding clo-
zapine, which must be prescribed only for refractory cases 
[11], again similar to guidelines in other countries. This 
recommendation is mainly based on its adverse effects 
and tolerability profile [11, 48]. In our study, clozapine 
accounted for the highest average annual cost per patient 
due to psychiatric hospitalizations and outpatient psychi-
atric care. This suggests that patients treated with clozap-
ine have complicated disease that is refractory to other 
medications, which aligns with current clinical guidelines. 
Patients with disease that is refractory to other antipsy-
chotic drugs, or who have lower adherence to drug therapy, 
may have psychotic outbreaks and need hospitalization or 
outpatient care, contributing to increased costs. However, 
this needs to be shown in additional studies before any 
definitive statement can be made. Having said this, drug 
AA, atypical antipsychotic; CLO, clozapine; OLA, olanzapine; QUE, quetiapine; RIS, risperidone; ZIP, ziprasidone
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Fig. 2  Forest plot showing percentage difference of the mean annual 
cost per patient with 95% confidence intervals from the multivariate 
log-linear regression model. Brazil, 2000–2010. AA atypical antipsy-
chotic, CI confidence interval, CLO clozapine, OLA olanzapine, PD 
percentage difference, QUE quetiapine, RIS risperidone, ZIP ziprasi-
done
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switching and psychotic outbreaks were associated with an 
increase in the mean annual cost per patient in our study.
Psychiatric hospitalization resulted in the highest mean 
annual cost per patient and showed a growth trend during 
the follow-up years (Fig. 1). Since the 1970s, Brazil has been 
following the development of a complex political and social 
process called the Psychiatric Reform, which encourages 
dehospitalisation of patients with mental disorders, directing 
these patients to community treatment, with an emphasis on 
outpatient care [54–56]. The results in this cohort reinforce 
the dehospitalisation policy for psychiatric patients in Bra-
zil since outpatient psychiatric care had the lowest mean 
annual cost per patient, with a tendency for these costs to be 
reduced during the follow-up years (Fig. 1). In view of this, 
improving ambulatory care management of patients with 
schizophrenia is an essential component to optimize the use 
of available resources. We will be researching this in Brazil 
in the future, including looking more closely at adherence 
rates for atypical antipsychotics in routine ambulatory care, 
with relapses appreciably increasing costs [57]. This further 
research will build on our initial findings.
We accept that, since this cohort was established from 
administrative databases, information may be incomplete 
or inconsistent, problems that are inherent to retrospective 
studies using secondary databases. This means that some 
clinical information is missing, such as time of diagnosis, 
information using the Positive and Negative Syndrome 
Scale and the Brief Psychiatric Rating Scale, and reasons 
for switching atypical antipsychotics. Furthermore, the tabu-
lated values are taken directly from the SUS database (SIA 
and SIH) and were not further validated after the data were 
entered onto the national systems and represent an estimate 
of actual costs because they are the amounts reimbursed by 
the federal government. We also could not include the costs 
of typical antipsychotics that were not included in the SUS 
database. Finally, we are aware that some patients used the 
private sector (health plan or direct payment) for outpatient 
and hospital treatment, which potentially distorts our find-
ings. Despite these limitations, we believe our comprehen-
sive methodology has led to robust findings that provide 
direction for the future.
5  Conclusion
In this 11-year nationwide cohort, high-cost drugs, includ-
ing atypical antipsychotics, drug switching and psychotic 
outbreaks, were the principal contributors to the mean 
annual costs per patient with schizophrenia, with atypical 
antipsychotics responsible for the majority of direct costs. 
However, this is influenced by the availability of generally 
only patented atypical antipsychotics (antipsychotic origi-
nator) during the study period. Psychiatric hospitalization 
was associated with a higher mean annual cost per patient 
than were atypical antipsychotics and outpatient psychiat-
ric care and should be avoided where possible by improv-
ing ambulatory care services. Patients prescribed clozapine 
had the highest mean annual cost per patient for outpatient 
psychiatric care and psychiatric hospitalization, suggesting 
these patients have complicated disease requiring additional 
attention, including hospitalization.
It is important to highlight that public policies and deci-
sion making should not be based exclusively on costs and 
should also consider outcomes and health indicators. Lastly, 
the results of this analysis of real-world data can be used to 
inform future strategies of the NHS, in Brazil and globally, 
and suggests a need to ensure effective use of atypical antip-
sychotics and encourage outpatient psychiatric care where 
possible to reduce psychiatric hospitalization.
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